- Home
- PTA vs JANX Comparison
PTA vs JANX Comparison
Compare PTA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTA | JANX |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.4M | 975.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PTA | JANX |
|---|---|---|
| Price | $18.07 | $16.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 216.3K | ★ 847.3K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.52 | $12.12 |
| 52 Week High | $20.92 | $35.34 |
Technical Indicators
Market Signals| Indicator | PTA | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 45.57 |
| Support Level | N/A | $13.09 |
| Resistance Level | $19.61 | $19.14 |
| Average True Range (ATR) | 0.22 | 0.79 |
| MACD | 0.01 | -0.35 |
| Stochastic Oscillator | 48.65 | 20.14 |
Price Performance
Historical ComparisonAbout PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.